◆ TICKERBASEOpen interactive view →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksA › ALGN

Align Technology Inc (ALGN) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · Health Care Supplies · DATA UPDATED 2026-09-19

Align Technology Inc (ALGN) operates in the Health Care Supplies industry and is headquartered in Tempe, United States with about 20,435 employees. Its market capitalization is roughly $10 billion. In the fiscal year ended 2025-12-31, ALGN reported $4.0B in revenue and $410M in net income.

Align Technology, Inc. provides Invisalign clear aligners, Vivera retainers, and iTero intraoral scanners and services in the United States, Switzerland, and internationally.

Interactive charts & full statements → Open the ALGN valuation workbench →

ALGN Revenue & Earnings History — Annual Income Statement

Income statementTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-31
Total Revenue$4.1B$4.0B$4.0B$3.9B$3.7B$4.0B$2.5B$2.4B$2.0B$1.5B$1.1B$845M$762M$660M$560M$480M$387M$312M$304M$284M$206M
Gross Profit$2.8B$2.8B$2.8B$2.7B$2.6B$2.9B$1.8B$1.7B$1.4B$1.1B$815M$640M$578M$498M$416M$361M$303M$233M$225M$209M$142M
Gross Margin %68.1%68.3%70.0%70.1%70.5%74.3%71.3%72.5%73.6%75.8%75.5%75.7%75.9%75.4%74.4%75.3%78.4%74.8%74.1%73.6%68.6%
Operating Income (EBIT)$622M$616M$608M$643M$643M$976M$387M$542M$467M$354M$249M$189M$194M$94M$86M$90M$103M($34M)$16M$34M($38M)
Operating Margin %15.0%15.3%15.2%16.7%17.2%24.7%15.7%22.5%23.7%24.0%23.1%22.3%25.4%14.3%15.3%18.8%26.5%-10.9%5.1%11.9%-18.2%
Net Income$414M$410M$421M$445M$362M$772M$1.8B$443M$400M$231M$190M$144M$146M$64M$59M$67M$74M($31M)$80M$36M($35M)
Net Margin %10.0%10.2%10.5%11.5%9.7%19.5%71.8%18.4%20.3%15.7%17.6%17.0%19.1%9.7%10.5%13.9%19.2%-10.0%26.3%12.6%-16.9%
EBITDA$766M$817M$643M$780M$1.1B$481M$593M$521M$391M$273M$207M$211M$178M$140M$108M$121M($21M)$30M$47M($27M)
Earnings Per Share (EPS)$5.75$5.65$5.62$5.81$4.61$9.69$22.41$5.53$4.92$2.83$2.33$1.77$1.77$0.78$0.71$0.83$0.95$-0.45$1.18$0.50$-0.55
Shares Outstanding (M)73M75M77M78M80M79M80M81M82M81M82M82M83M83M80M78M69M68M71M63M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ALGN Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Total Revenue$1.1B$1.0B$1.0B$996M$1.0B$979M$995M$978M$1.0B
Gross Profit$757M$737M$688M$639M$708M$680M$697M$682M$723M
Gross Margin %71.7%70.8%65.7%64.2%69.9%69.5%70.0%69.7%70.3%
Operating Income (EBIT)$193M$173M$160M$96M$163M$131M$144M$162M$147M
Operating Margin %18.3%16.6%15.2%9.7%16.1%13.4%14.5%16.6%14.3%
Net Income$108M$113M$136M$57M$125M$93M$104M$116M$97M
Net Margin %10.2%10.8%13.0%5.7%12.3%9.5%10.4%11.9%9.4%
EBITDA$205M$279M$212M$214M$174M$215M$200M$214M
Earnings Per Share (EPS)$1.51$1.57$1.89$0.78$1.72$1.27$1.39$1.55$1.28
Shares Outstanding (M)72M72M72M73M74M74M75M75M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ALGN Free Cash Flow History

Cash flowTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-31
Cash from Operations (CFO)$756M$593M$738M$786M$569M$1.2B$662M$747M$555M$439M$248M$238M$227M$186M$134M$130M$130M$74M$40M$53M($14M)
Capital Expenditures (CapEx)$201M$102M$116M$178M$292M$401M$155M$150M$223M$196M$71M$53M$24M$19M$38M$30M$18M$7M$14M$7M$24M
Free Cash Flow (FCF)$556M$491M$623M$608M$277M$771M$507M$598M$331M$243M$177M$185M$203M$167M$95M$100M$111M$67M$25M$45M($38M)
FCF Margin %13.4%12.2%15.6%15.7%7.4%19.5%20.5%24.8%16.9%16.5%16.4%21.8%26.6%25.2%17.0%20.9%28.8%21.4%8.4%16.0%-18.4%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ALGN Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Cash from Operations (CFO)$193M$151M$223M$189M$129M$53M$286M$264M$160M
Capital Expenditures (CapEx)$36M$31M$67M$67M$25M$25M$23M$30M$53M
Free Cash Flow (FCF)$157M$120M$157M$122M$103M$27M$263M$234M$106M
FCF Margin %14.9%11.6%14.9%12.3%10.2%2.8%26.4%23.9%10.3%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ALGN Balance Sheet History

Balance sheet2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-31
Total Assets$6.4B$6.2B$6.2B$6.1B$5.9B$5.9B$4.8B$2.5B$2.1B$1.8B$1.4B$1.2B$988M$832M$756M$649M$477M$355M$279M$223M$152M
Cash & Cash Equivalents$1.1B$1.1B$1.0B$937M$942M$1.1B$961M$550M$637M$450M$389M$168M$200M$243M$306M$241M$295M$166M$87M$89M$55M
Total Liabilities$2.2B$2.2B$2.4B$2.5B$2.3B$2.3B$1.6B$1.2B$800M$627M$401M$311M$235M$198M$175M$158M$99M$82M$61M$62M$68M
Total Debt (Short + Long-Term)$32M$31M$30M$27M$23M$22M$16M$12M$18M$9M$7M$7M$7M$9M$73M$56M$0M$0M$0M$12M
Total Shareholders' Equity$4.2B$4.0B$3.9B$3.6B$3.6B$3.6B$3.2B$1.3B$1.3B$1.1B$995M$848M$753M$634M$581M$491M$378M$273M$219M$161M$84M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ALGN viewer.

ALGN Metric Deep Dives

Other Companies in Health Care Supplies

This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी

← ALGMAll “A” companiesALGOQUANT →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.